Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

• Status: Not yet recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective of the study is to study the pharmacokinetics of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.

The secondary objective of the study is to evaluate the safety and efficacy (ORR) of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
• Treatments: Docetaxel; Trastuzumab

Criteria

Inclusion Criteria:

1. HER2 positive recurrent or metastasis breast cancer.

2. Patients with measurable disease are eligible.

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

4. Adequate organ function.

5. Signed, written inform consent obtained prior to any study procedure.

Exclusion Criteria:

1. Patients received more than 1 line of chemotherapy, or more than 1 line of endocrine therapy, or received targeted therapy and immunotherapy in the phase of recurrence / metastasis.

2. History of HER tyrosine kinase inhibitors or monoclonal antibody for breast cancer in any treatment setting，except trastuzumab used in the neo-adjuvant or adjuvant setting.

3. Assessed by the investigator to be unable receive systemic chemotherapy.

4. History of other malignancy within the last 5 years，except for carcinoma in situ of cervix，basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent.

5. Pregnant or lactating women，or for women of childbearing potential unwilling to use a highly-effective contraception during of the study treatment and for at least 7 months after the last dose of study treatment.